Marshall Wace
CTMX icon

Marshall Wace’s CytomX Therapeutics CTMX Stock Holding History

Marshall Wace’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
3,024,351
-1,113,825
-27% -$4.25M 0.01% 985
2026
Q1 		$19.4M Buy
4,138,176
+2,981,240
+258% +$15.1M 0.02% 714
2025
Q4 		$4.93M Buy
1,156,936
+51,943
+5% +$197K ﹤0.01% 1167
2025
Q3 		$3.52M Sell
1,104,993
-1,248,129
-53% -$2.81M ﹤0.01% 1348
2025
Q2 		$5.34M Buy
2,353,122
+2,267,583
+2,651% +$3.66M 0.01% 1108
2025
Q1 		$54.7K Buy
+85,539
New +$66.3K ﹤0.01% 2531
2024
Q2 		– Sell
-52,289
Closed -$114K – 2616
2024
Q1 		$114K Sell
52,289
-310,987
-86% -$574K ﹤0.01% 2297
2023
Q4 		$563K Sell
363,276
-14,317
-4% -$18.8K ﹤0.01% 1680
2023
Q3 		$487K Sell
377,593
-296,908
-44% -$467K ﹤0.01% 1735
2023
Q2 		$1.16M Sell
674,501
-55,437
-8% -$92K ﹤0.01% 1649
2023
Q1 		$1.1M Buy
+729,938
New +$1.65M ﹤0.01% 1762
2022
Q4 		– Sell
-40,021
Closed -$58K – 3000
2022
Q3 		$58K Sell
40,021
-24,123
-38% -$37.1K ﹤0.01% 3232
2022
Q2 		$118K Buy
64,144
+48,878
+320% +$93.6K ﹤0.01% 3254
2022
Q1 		$40K Buy
+15,266
New +$58.6K ﹤0.01% 3253
2020
Q2 		– Sell
-117,393
Closed -$900K – 1615
2020
Q1 		$900K Sell
117,393
-284,033
-71% -$1.98M 0.01% 824
2019
Q4 		$3.34M Buy
401,426
+393,401
+4,902% +$2.65M 0.02% 662
2019
Q3 		$59K Buy
+8,025
New +$79.2K ﹤0.01% 1470
2019
Q1 		– Sell
-51,876
Closed -$783K – 1772
2018
Q4 		$783K Sell
51,876
-28,532
-35% -$423K 0.01% 977
2018
Q3 		$1.49M Buy
+80,408
New +$1.83M 0.01% 736
2018
Q2 		– Sell
-12,100
Closed -$344K – 726
2018
Q1 		$344K Buy
+12,100
New +$345K 0.01% 440

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Marshall Wace's CTMX Position: Q2 2026 in Review

Marshall Wace reduced its CytomX Therapeutics (CTMX) stake by 27% in Q2 2026, selling an estimated $4.25M and leaving 3,024,351 shares worth $11.3M. The position accounts for 0.01% of the portfolio, ranked #985.

Marshall Wace first reported a position in CTMX in Q1 2018 and has held it in 20 quarters since. The position peaked at $19.4M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Marshall Wace held 3,024,351 shares of CytomX Therapeutics worth $11.3M as of Q2 2026.
  • Marshall Wace sold 1,113,825 CytomX Therapeutics shares in Q2 2026, an estimated $4.25M.
  • CytomX Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #985 holding.
  • Marshall Wace first reported a position in CytomX Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • Marshall Wace's CytomX Therapeutics position peaked at $19.4M in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.